FDA approves combo test for flu, COVID-19; alerts providers to medical device risks
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19. The OSOM Flu SARS-CoV-2 Combo Home Test is authorized for use to detect and differentiate influenza A and B and SARS-CoV-2 in nasal swab specimens from people aged 14 and older when conducted at least twice over three days with at least 48 hours between tests.
In other news, the FDA last week recommended health care providers monitor patients with the Hintermann Series H3 Total Ankle Replacement system for potential device failure, and patients with certain implantable BioZorb breast tissue markers for potential serious complications.
Related News Articles
Headline
The Centers for Disease Control and Prevention today released an advisory recommending clinicians expedite subtyping of type A influenza samples from…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Louisiana Department of Health yesterday announced that a patient hospitalized last month for H5N1 bird flu has died, becoming the first U.S. death from…
Headline
AHA’s latest social media toolkit for encouraging vaccination against the flu and COVID-19 focuses on vaccination during peak respiratory virus season. The…
Headline
The Food and Drug Administration Dec. 31 released an alert highlighting a Baxter letter that recommended health care providers not use certain lots of Solution…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…